Strategies to minimize complications of ERCP

John G. Lee, MD | February 22, 2019



Disclosure

Cook Endoscopy

Advanced Sterilization Products



Common complications of ERCP

- Pancreatitis
- Bleeding
- Infection
- Perforation
- Cardiopulmonary
- Death





Only absolute way to eliminate the risk of ERCP...

- Anything related to SOD
 - No evidence for 'type III'
 - No evidence for causing pancreatitis
 - Indefensible indication for ERCP
- Most diagnostic ERCP

FAKE NEWS NETWORK

"ERCP is most dangerous to those who need it the least..."





Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials

- Over all incidence was 9.7% with mortality of 0.7%
 - Mild in 5.7%
 - Moderate in 2.6%
 - Severe in 0.5%
- Incidence in 'high risk' patients was 14.7%
- Incidence in North America was 13%
 - Europe was 8.4%
 - Asian 9.9%
- Incidence before 2000 was 7.7%
- Incidence after 2000 was 10%

GIE 2015;81:143-149



Independent risk factors for post-ERCP pancreatitis identified with multivariable analysis

Patient-related risk factors	
Prior post-ERCP pancreatitis	8.7 (3.2-23.86)
Female sex	3.5 (1.1-10.6)
Previous recurrent pancreatitis	2.46 (1.93-3.12)
Suspected sphincter of Oddi dysfunction	1.91 (1.37-2.65)
Younger patient age (<40 years old) 30 vs 70 years old	1.8 (1.27-2.59) 2.14 (1.413.25)
Absence of chronic pancreatitis	1.87 (1.003.48)
Normal serum bilirubin	1.89 (1.222.93)
Procedure-related risk factors	
Difficult cannulation (>10 minutes)	1.76 (1.13-2.74)
Repetitive pancreatic guidewire cannulation	2.77 (1.79-4.30)
Pancreatic injection	2.2 (1.60-3.01)
Pancreatic sphincterotomy	3.07 (1.64-5.75)
Endoscopic papillary large-balloon dilation of an intact sphincter	4.51 (1.51-13.46)

Risk is additive!



Strategies to minimize risk of pancreatitis besides patient selection

- Hydration
- Medication
- Endoscopy technique
 - Pancreatic stenting
 - Guidewire cannulation
 - Early precut





Aggressive hydration with lactated ringers

- Aggressive hydration with lactated Ringer's solution reduces pancreatitis after endoscopic retrograde cholangiopancreatography
 - Clin Gastroenterol Hepatol 2014 Feb;12(2):303-7
 - 0% versus 17% post ERCP pancreatitis
- Aggressive hydration with Lactated Ringer's solution as the prophylactic intervention for postendoscopic retrograde cholangiopancreatography pancreatitis: A randomized controlled double-blind clinical trial
 - J Res Med Sci. 2015;20(9):838
 - 5.3% versus 22.7% (P = 0.002) post ERCP pancreatitis
- 3ml/kg/h during and after ERCP x 8 hours + 20ml/kg bolus post procedure
- Data are weak but no reason not to use it



Indomethacin





		Patients with PEP		
		Indomethacin (n=16)	Placebo (n=11)	% Relative Risk Reduction (Indomethacin vs. Placebo)
			. (2.5)	
L	Pancreatic Stent Placement – no. (%)	8 (50)	4 (36)	-28%
	Suspected Sphincter of Oddi Dysfunction – no. (%)	1 (6)	1 (9)	+33%
	History of Post-ERCP Pancreatitis	2 (13)	1 (9)	-21%
l	Difficult Cannulation	6 (38)	5 (45)	+16%
	Wire Cannulation of Pancreatic Duct – no. (%)	13 (81)	7 (64)	-21%
	Pancreatography – no. (%)	8 (50)	8 (73)	+32%
	Pancreatic Acinarization – no. (%)	2 (13)	0 (0)	NA
	Therapeutic Biliary Sphincterotomy – no. (%)	7 (44)	3 (27)	-39%
ſ	Therapeutic Pancreatic Sphincterotomy – no. (%)	2 (13)	3 (27)	+52%
1	Balloon Dilation of Biliary Sphincter – no. (%)	0 (0)	1 (9)	NA
	Trainee Involvement in ERCP – no. (%)	12 (75)	8 (73)	-3%


Gastroenterology. 2016 Apr; 150(4): 911–917.

- PR Indomethacin 50mg x 2
- Appears to work, especially in high risk
- No harm, so why not?
 - Contraindication anaphylaxis, pregnancy





Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial



- Double blinded PCT
- But high pancreatitis rate
- But still makes sense

GIE, 2017 (85), 1005-1013

- What about aggressive intra and post procedure hydration?
- Beware of increased serum lactate level
- No reason not to use LR + indomethacin




Updated meta-analysis of pancreatic stent placement in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis

}	Stent		No stent			Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H, fixed, 95%CI	M-H, fixed, 95%CI
2.1.1 Mild							
Cha 2012	2	46	5	58	3.70%	0.48 [0.09, 2.61]	- •
Fazel 2003	2	40	7	36	6.10%	0.22 [0.04, 1.13]	
Harewood 2005	1	11	3	8	2.80%	0.17 [0.01, 2.04]	-
Ito 2010	1	35	8	35	6.80%	0.10 [0.01, 0.84]	-
Karaguchi 2012	1	60	8	60	6.90%	0.11 [0.01, 0.91]	
Lee 2012	6	50	14	51	10.70%	0.36 [0.13, 1.03]	
Smithline 1993	6	48	7	50	5.30%	0.88 [0.27, 2.83]	
Sofuni 2007	3	98	14	103	11.60%	0.20 [0.06, 0.72]	
Sofuni 2011	20	213	30	213	23.80%	0.63 [0.35, 1.15]	
Thanasky 1998	3	43	10	39	8.60%	0.22 [0.05, 0.86]	
Tsuchiya 2007	1	32	3	32	2.50%	0.31 [0.03, 3.17]	-
Subtotal (95%CI)		676		685	88.90%	0.38 [0.26, 0.54]	♦
Total events	46		109				
Heterogeneity: $\chi^2 = 10^{-1}$	0.13, $df = 10$	(P = 0.43)); I ² = 1%				
Test for overall effect:	Z = 5.24 (P - 1)	< 0.00001)				
24.25							
2.1.2 Severe						0.01.50.01.5.403	
Cha 2012	0	46	2	58	1.90%	0.24 [0.01, 5.19]	
Fazel 2003	0	40	3	36	3.20%	0.12 [0.01, 2.37]	
Lee 2012	0	50	1	51	1.30%	0.33 [0.01, 8.38]	•
Smithline 1993	0	48	2	50	2.10%	0.20 [0.01, 4.28]	
Sofuni 2011	0	213	1	213	1.30%	0.33 [0.01, 8.19]	-
•	0	32	1	32	1.30%	0.32 [0.01, 8.23]	
Tsuchiya 2007 Subtotal (95%CI)		32 429		32 440	1.30% 11.10%	0.32 [0.01, 8.23] 0.23 [0.06, 0.81]	•
Subtotal (95%CI) Total events	0	429	10				
Subtotal (95%CI) Total events Heterogeneity: $\chi^2 = 0$	0 .34, <i>df</i> = 5 (<i>F</i>	429 ? = 1.00); .	10				
Subtotal (95%CI) Total events Heterogeneity: $\chi^2 = 0$	0 .34, <i>df</i> = 5 (<i>F</i>	429 ? = 1.00); .	10				
Subtotal (95%CI) Total events Heterogeneity: $\chi^2 = 0$. Test for overall effect:	0 .34, <i>df</i> = 5 (<i>F</i>	429 ? = 1.00); ; = 0.02)	10	440	11.10%	0.23 [0.06, 0.81]	•
Subtotal (95%CI) Total events Heterogeneity: $\chi^2 = 0$. Test for overall effect: Total (95%CI)	0 .34, <i>df</i> = 5 (<i>P</i> : <i>Z</i> = 2.28 (<i>P</i> :	429 ? = 1.00); .	10 I ² = 0%				•
Subtotal (95%CI) Total events Heterogeneity: $\chi^2 = 0$. Test for overall effect: Total (95%CI) Total events	0 .34, df = 5 (F Z = 2.28 (P =	429 ? = 1.00); ; = 0.02) 1105	I_{10} $I_{2} = 0\%$ I_{119}	440 1125	11.10%	0.23 [0.06, 0.81]	•
Subtotal (95%CI) Total events Heterogeneity: $\chi^2 = 0$. Test for overall effect: Total (95%CI)	0 = 34, df = 5 (P = 2.28 (P = 46)) $46 = 1.10, df = 16$	429 $P = 1.00$); $P = 0.02$ $P = 0.80$	10 $I^2 = 0\%$ 119); $I^2 = 0\%$	440 1125	11.10%	0.23 [0.06, 0.81]	0.01 0.1 1 10 100



The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement



- Not randomized; intent to stent unclear in a retrospective review
- Why was pancreatitis so common after failed stent?
 - Excessive attempt ('beating up' the papilla);
 - Intrinsically high risk patients in Indiana, i.e., so called SOD patients?
- Indomethacin is possibly protective after failed stenting
- So place PD stent only if 'easy'



Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis

Outcomes	Illustrative comparative risks* (9 Assumed risk Contrast-assisted cannulation, Main analysis	Corresponding risk Guidewire-assisted cannulation	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Post-ERCP pancreatitis (ITT)	67 per 1000	34 per 1000 (22 to 55)	RR 0.51 (0.32 to 0.82)	3450 (12 studies)	⊕⊕⊕⊝ moderate ^{1,2}	NNT was 31 (95% CI 19 to 78)

^{*}The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;


- Higher selective cannulation rate (RR 1.07, 95% CI 1.00 to 1.15)
- Less precut sphincterotomy (RR 0.75; 95% CI, 0.60-0.95)
 - But no difference in studies that allowed cross over
- Really no reason not to use guidewire cannulation

Cochrane Database of Systematic Reviews 2012, Issue 12.




Cannulation technique after PD is accessed first

- Maintain wire in PD
- Cut towards the biliary orifice
 - Look for bile
- Place 5fr x 5cm fall out stent using sphincterotome as pusher
- Reattempt cannulation towards the biliary orifice
 - Earlier precut needle knife sphincterotomy for access
 - Repeat next day if still unable to access after precut
 - Alternative cannulation techniques
 - EUS guided rendezvous
 - EUS choledochoduodenostomy
 - Percutaneous approach





Early Precut Sphincterotomy Does Not Increase Risk During Endoscopic Retrograde Cholangiopancreatography in Patients With Difficult Biliary Access: A Meta-analysis of Randomized Controlled Trials



- Highly variable definition of difficult cannulation almost impossible to prove...
 - 5-12 minute attempt or >2-4 PD cannulation
- Early precut is probably better if it can be done 'safely'



Strategies to minimize risk of pancreatitis

- Crystal clear indications
- Do everything with low to no risk
 - Hydration with LR
 - PR indomethacin
 - Guidewire cannulation
- PD stent if easy
- Consider early precut for access



Complications of endoscopic biliary sphincterotomy – significant risk factors for post sphincterotomy bleeding

- Coagulopathy (OR 3.32; P < .001)
- Active cholangitis (OR 2.59; P < .001)
- Anticoagulant therapy within 3 days after ERCP (OR 5.11;
 P < .001)
- Endoscopist case volume ≤1 per week (OR 2.17; P = .002)
- Any observed bleeding during the procedure (OR 1.74; P = .004)

NEJM 1996;335, 909-918



Bleeding risk

- Assume high risk
 - Unrecognized coagulopathy and importance of bleeding history
 - Exceptions prior sphincterotomy or stent change
- Cardiology / Neurology / anticoagulation clinic when in doubt
- Warfarin
 - Hold 3-5 days, +/- check INR, restart immediately to 2-3 days
- DOAC
 - Dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysal)
 - Hold 48 hours, restart immediately to 3 days
- Antiplatelet therapy
 - Usually continue aspirin / NSAID
 - Usually hold P2Y₁₂ e.g., ticlopidine (Ticlid), clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta) for 5-14 days; continue aspirin if on dual therapy

Decreasing bleeding risk

- Don't cut unless necessary
- Blended / microprocessor controlled cutting might be better than pure cutting current
- Do not cut with too much wire
- Do not tent too much




Minimizing infection risk

- Meticulous reprocessing
- Use of sterile accessories whenever possible including water, water bottle, tubing etc.
- Prophylactic antibiotics not recommended except for
 - Post OLT patient
 - Incomplete drainage
 - Retained stones / sludge
 - Over filling of complex hilar strictures



Risk of infection with hilar stricture





- MRCP first
- Inject only if absolutely necessary
- Always inject proximal to stricture
- Inject each side separately and only after wire access in contralateral side




Risk factors for perforation

- Surgically altered anatomy
- Recent surgery
- Stricture / cancer
- Old age cervical spur
- Difficult cannulation
- Sphincterotomy
- Large balloon dilation
- Barotrauma
- Stiff wires, plastic stents, metal stent / introducer



Perforation



Ann Surg. 2000 Aug;232(2):191-8.

- I limit dilation, cervical spur
- II cut between 11 1 O'clock, cut and dilate
- III hydrophilic guidewire, wire lock
- IV CO2, water

Immediate recognition is key!

- Strange air shadow / control film
- Difficulty insufflating
- Hemodynamic instability
- Crepitus, tense abdomen
- Pain

Table 1. Classification of latrogenic Duodenal Perforations during Endoscopic Retrograde Cholangiopancreatography

Reference	Type and definition				
Stapfer et al.1	Type I, lateral or medial duodenal wall perforation, endoscope related				
	Type II, periampullary perforations, sphincterotomy related				
	Type III, ductal or duodenal perforations due to endoscopic instruments				
	Type IV, guidewire-related perforation with presence of retroperitoneal air at X-ray				
Howard et al.2	Group I, guidewire perforation				
	Group II, periampullary perforation				
	Group III, duodenal perforation				
Enns et al.3	Esophageal, gastric, and duodenal perforation				
	Sphincterotomy-related perforation				
	Guidewire-related perforation				



ASGE recommendations

- 1. Use techniques that reduce the risk of pancreatitis (i.e., wire-guided cannulation, prophylactic pancreatic duct stenting). ⊕⊕⊕⊕
- 2. Pancreatic duct stenting in high-risk individuals. ⊕⊕⊕⊕
- 3. Follow FDA recommendations for duodenoscope reprocessing. $\oplus \oplus \oplus \oplus$
- 4. Early precut for difficult biliary cannulation when expertise is available. ⊕⊕⊕∘
- 5. Rectal nonsteroidal anti-inflammatory drugs (NSAIDS). ⊕⊕⊕∘
- 6. No large balloon dilation (EPLBD) of an intact sphincter. ⊕⊕⊕∘
- 7. Sphincterotomy only when absolutely indicated. ⊕⊕⊕∘
- 8. Use microprocessor-controlled generator with mixed current. $\oplus \oplus \oplus \circ$



ASGE recommendations

- 9. Antibiotic prophylaxis for OLT patients and possible incomplete biliary drainage; continue afterwards for incomplete biliary drainage. ⊕⊕⊕∘
- 10. Insufficient evidence that rectal NSAIDs + PD stenting is better than either technique alone for prevention of post-ERCP pancreatitis in high-risk individuals. ⊕⊕∘∘
- 11. Rectal indomethacin may reduce the risk and severity of post-ERCP pancreatitis in average-risk individuals. ⊕⊕∘∘
- 12. Non operative management for type II, III, IV perforations from ERCP without peritonitis or SIRS. ⊕⊕○○
- 13. No premedication in patients with food or IV contrast allergies. ⊕⊕∘∘
- 14. Periprocedural IV LR hydration. ⊕○○○



